The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis

• Main Authors: Sirio Fiorino, Carmela Cursaro, Stefania Lorenzini, Elisabetta Loggi, Lucia Brodosi, Laura Cattani, Andrea Cuppini, Mauro Bernardi, Pietro Andreone
• Format: Article
• Language: English
• Published: PAGEPress Publications 2013-03-01
• Series: Italian Journal of Medicine
• Subjects: Prostaglandin E2; Hepatitis B Virus; Hepatitis C Virus; Chronic hepatitis; Non-steroidal antiinflammatory drugs (NSAIDs).
• Online Access: http://www.italjmed.org/index.php/ijm/article/view/131
• ISSN: 1877-9344; 1877-9352

Introduction: Different DNA and RNA viruses exploit common strategies to support their persistence and replication in infected individuals. In particular, the hepatitis B virus (HBV) and the hepatitis C virus (HCV) cause major health problems worldwide. These pathogens exert an immunosuppressive role by inducing the persistent activation of cyclooxygenase-2 (COX-2) and an increased synthesis of prostaglandin E2 (PGE2). The suppression of this proinflammatory network by non-steroidal anti-inflammatory drugs (NSAIDs) has been proposed as a therapeutic approach to decrease viral replication. <br />Materials and methods: In this review, the role of inflammation in the support of viral replication and NSAIDs and ketoprofen pharmacology are briefly discussed. In addition, studies that have investigated the use of NSAIDs for the treatment of HBV and HCV chronic hepatitis, which were identified by a systematic literature search of PubMed and MEDLINE, are reported. <br />Results: To date, pegylated-interferon (PEG-IFN) and/or nucleot(s)ide analogues and PEG-IFN and ribavirin remain the standard therapy for HBV and HCV chronic hepatitis, respectively. <br />Discussion: The use of NSAIDs in patients with chronic viral hepatitis has only a ‘‘historical’’ interest. Nevertheless, the possible usefulness of ketoprofen with PEG-IFN and ribavirin for HCVinfected patients, non-responders to standard therapy or with genotype 1, should be evaluated in future clinical studies.